Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Hemophagocytic Lymphohistiocytosis
and you are
between 14 and 75
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

This study aimed to investigate the efficacy and safety of Pegaspargase together with liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as an initial treatment for Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.

Provided treatments

  • Drug: Pegaspargase
  • Drug: doxorubicin hydrochloride liposome injection
  • Drug: etoposide
  • Drug: methylprednisolone
  • Drug: Etoposide
  • Drug: dexamethasone
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02912702. The sponsor of the trial is Beijing Friendship Hospital and it is looking for 120 volunteers for the current phase.
Official trial title:
A Randomized Controlled Trial of L-DEP as an Initial Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis